TLP
AVDL

Tri Locum Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Tri Locum Partners’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-724,859
Closed -$11.1M – 17
2025
Q3 		$11.1M Sell
724,859
-289,597
-29% -$3.77M 2.54% 13
2025
Q2 		$8.98M Buy
+1,014,456
New +$8.91M 2.72% 14
2025
Q1 		– Sell
-1,937,984
Closed -$20.4M – 23
2024
Q4 		$20.4M Buy
1,937,984
+277,029
+17% +$3.36M 4.22% 9
2024
Q3 		$21.8M Buy
1,660,955
+471,437
+40% +$7.18M 5.22% 8
2024
Q2 		$16.7M Buy
1,189,518
+7
+0% +$114 4.23% 12
2024
Q1 		$20.1M Buy
1,189,511
+349,578
+42% +$5.21M 6.97% 2
2023
Q4 		$11.9M Sell
839,933
-143,669
-15% -$1.69M 5.42% 7
2023
Q3 		$10.1M Sell
983,602
-55,872
-5% -$748K 3.24% 9
2023
Q2 		$17.1M Sell
1,039,474
-287,623
-22% -$3.74M 6.37% 3
2023
Q1 		$12.2M Buy
1,327,097
+642,541
+94% +$5.28M 3.7% 10
2022
Q4 		$4.9M Buy
+684,556
New +$4.8M 1.98% 19
2021
Q4 		– Sell
-148,355
Closed -$1.45M – 42
2021
Q3 		$1.45M Sell
148,355
-165,440
-53% -$1.3M 0.58% 25
2021
Q2 		$2.11M Buy
313,795
+153,539
+96% +$1.22M 0.69% 24
2021
Q1 		$1.45M Buy
+160,256
New +$1.3M 0.36% 30

Other funds holding AVDL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tri Locum Partners's AVDL Position: Q4 2025 in Review

Tri Locum Partners sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 724,859 shares — an estimated $11.1M sold.

Tri Locum Partners first reported a position in AVDL in Q1 2021 and held it in 14 quarters. The position peaked at $21.8M in Q3 2024. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

  • Tri Locum Partners reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Tri Locum Partners sold 724,859 Avadel Pharmaceuticals shares in Q4 2025, an estimated $11.1M.
  • Tri Locum Partners first reported a position in Avadel Pharmaceuticals in Q1 2021 and held it in 14 quarters.
  • Tri Locum Partners's Avadel Pharmaceuticals position peaked at $21.8M in Q3 2024.
  • 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on Tri Locum Partners's 13F filing for Q4 2025, filed 17 Feb 2026.